Last reviewed · How we verify
NCT04553874
Health Status of the Oldest-old Population
trial in the Health Status of the Oldest Old in 800 participants. Status unknown.
30 June 2022
Quick facts
| Lead sponsor | Peking University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 800 |
| Start date | 1 December 2020 |
| Primary completion | 30 June 2022 |
| Estimated completion | 30 June 2023 |
| Sites | 1 location across China |
Conditions studied
- the Health Status of the Oldest Old — all drugs for the Health Status of the Oldest Old →
Sponsor
Peking University
Who can join
80 and older, any sex, with the Health Status of the Oldest Old. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to investigate the health status of the oldest-old population and to explore the key factors associated with their quality of life The study will select all the elderly aged 85 years and above from Lanqiying Community, Qinghuayuan Street, Haidian District, Beijing, and enroll them after informed consent. Demographic, sociological, economic, physiological information and disease-related records will be collected through questionnaire interviews, scales, and examinations. After the first survey, the participants will be followed for 2 years to collect information about deaths or major health events. The baseline survey will be re-conducted two years later.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04553874
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Peking University trials
Trials by the same sponsor.
- NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
- NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
- NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
- NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
- NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04553874 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University
- Last refreshed: 28 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04553874.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing